229 related articles for article (PubMed ID: 36879271)
1. DEPROMP Trial: the additive value of PSMA-PET/CT-guided biopsy for prostate cancer management in biopsy naïve men-study protocol for a randomized trial.
Krausewitz P; Bundschuh RA; Gaertner FC; Essler M; Attenberger U; Luetkens J; Kristiansen G; Muders M; Ohlmann CH; Hauser S; Ellinger J; Ritter M
Trials; 2023 Mar; 24(1):167. PubMed ID: 36879271
[TBL] [Abstract][Full Text] [Related]
2. Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer.
Amin A; Blazevski A; Thompson J; Scheltema MJ; Hofman MS; Murphy D; Lawrentschuk N; Sathianathen N; Kapoor J; Woo HH; Chalasani V; Rasiah K; van Leeuwen PJ; Tang R; Cusick T; Stricker P; Emmett L
BJU Int; 2020 Apr; 125(4):515-524. PubMed ID: 31957122
[TBL] [Abstract][Full Text] [Related]
3. The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study.
Emmett L; Buteau J; Papa N; Moon D; Thompson J; Roberts MJ; Rasiah K; Pattison DA; Yaxley J; Thomas P; Hutton AC; Agrawal S; Amin A; Blazevski A; Chalasani V; Ho B; Nguyen A; Liu V; Lee J; Sheehan-Dare G; Kooner R; Coughlin G; Chan L; Cusick T; Namdarian B; Kapoor J; Alghazo O; Woo HH; Lawrentschuk N; Murphy D; Hofman MS; Stricker P
Eur Urol; 2021 Dec; 80(6):682-689. PubMed ID: 34465492
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic performance of
Ferraro DA; Becker AS; Kranzbühler B; Mebert I; Baltensperger A; Zeimpekis KG; Grünig H; Messerli M; Rupp NJ; Rueschoff JH; Mortezavi A; Donati OF; Sapienza MT; Eberli D; Burger IA
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3315-3324. PubMed ID: 33620559
[TBL] [Abstract][Full Text] [Related]
5. Clinical Trial Protocol for PRIMARY2: A Multicentre, Phase 3, Randomised Controlled Trial Investigating the Additive Diagnostic Value of [
Buteau JP; Moon D; Fahey MT; Roberts MJ; Thompson J; Murphy DG; Papa N; Mitchell C; De Abreu Lourenco R; Dhillon HM; Kasivisvanathan V; Francis RJ; Stricker P; Agrawal S; O'Brien J; McVey A; Sharma G; Levy S; Ayati N; Nguyen A; Lee SF; Pattison DA; Sivaratnam D; Frydenberg M; Du Y; Titus J; Lee ST; Ischia J; Jack G; Hofman MS; Emmett L
Eur Urol Oncol; 2024 Jun; 7(3):544-552. PubMed ID: 38061976
[TBL] [Abstract][Full Text] [Related]
6. The CONFIRM trial protocol: the utility of prostate-specific membrane antigen positron emission tomography/computed tomography in active surveillance for prostate cancer.
Bagguley D; Harewood L; McKenzie D; Ptasznik G; Ong S; Chengodu T; Woon D; Sim K; Sheldon J; Lawrentschuk N
BJU Int; 2024 Apr; 133 Suppl 4():27-36. PubMed ID: 37904302
[TBL] [Abstract][Full Text] [Related]
7. Dual-tracer PET/CT-targeted, mpMRI-targeted, systematic biopsy, and combined biopsy for the diagnosis of prostate cancer: a pilot study.
Qiu DX; Li J; Zhang JW; Chen MF; Gao XM; Tang YX; Zhang Y; Yi XP; Yin HL; Gan Y; Wang GL; Zu XB; Hu S; Cai Y
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2821-2832. PubMed ID: 34860277
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic Performance of Prostate-specific Membrane Antigen Positron Emission Tomography-targeted biopsy for Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis.
Kawada T; Yanagisawa T; Rajwa P; Sari Motlagh R; Mostafaei H; Quhal F; Laukhtina E; Aydh A; König F; Pallauf M; Pradere B; Ceci F; Baltzer PAT; Hacker M; Rasul S; Karakiewicz PI; Araki M; Nasu Y; Shariat SF
Eur Urol Oncol; 2022 Aug; 5(4):390-400. PubMed ID: 35715320
[TBL] [Abstract][Full Text] [Related]
9. Establishment and prospective validation of an SUV
Jiao J; Kang F; Zhang J; Quan Z; Wen W; Zhao X; Ma S; Wu P; Yang F; Guo W; Yang X; Yuan J; Shi Y; Wang J; Qin W
Theranostics; 2021; 11(17):8396-8411. PubMed ID: 34373749
[No Abstract] [Full Text] [Related]
10. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
11. Key learnings from concordant systematic biopsies in prostate-specific membrane antigen positron emission tomography/computed tomography-guided prostate biopsies: Enhancing targeting accuracy.
Büttner T; Gärtner F; Essler M; Weiten R; Kristiansen G; Ellinger J; Ritter M; Krausewitz P
Prostate; 2024 Jun; 84(8):772-779. PubMed ID: 38504659
[TBL] [Abstract][Full Text] [Related]
12.
Gondoputro W; Doan P; Katelaris A; Scheltema MJ; Geboers B; Agrawal S; Liu Z; Yaxley J; Savdie R; Rasiah K; Frydenberg M; Roberts MJ; Malouf D; Wong D; Shnier R; Delprado W; Emmett L; Stricker PD; Thompson J
Transl Androl Urol; 2023 Oct; 12(10):1598-1606. PubMed ID: 37969779
[TBL] [Abstract][Full Text] [Related]
13.
Liu C; Liu T; Zhang Z; Zhang N; Du P; Yang Y; Liu Y; Yu W; Li N; Gorin MA; Rowe SP; Zhu H; Yan K; Yang Z
J Nucl Med; 2020 Sep; 61(9):1314-1319. PubMed ID: 32034111
[TBL] [Abstract][Full Text] [Related]
14. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
Hofman MS; Murphy DG; Williams SG; Nzenza T; Herschtal A; Lourenco RA; Bailey DL; Budd R; Hicks RJ; Francis RJ; Lawrentschuk N
BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071
[TBL] [Abstract][Full Text] [Related]
15. PEDAL protocol: a prospective single-arm paired comparison of multiparametric MRI and 18F-DCPFyl PSMA PET/CT to diagnose prostate cancer.
Tran V; Hong A; Sutherland T; Taubman K; Lee SF; Lenaghan D; Sethi K; Corcoran NM; Lawrentschuk N; Woo H; Tarlinton L; Bolton D; Spelman T; Thomas L; Booth R; Hegarty J; Perry E; Wong LM
BMJ Open; 2022 Sep; 12(9):e061815. PubMed ID: 36123093
[TBL] [Abstract][Full Text] [Related]
16. Using prostate-specific membrane antigen positron-emission tomography to guide prostate biopsies and stage men at high-risk of prostate cancer.
Bodar YJL; Boevé LMS; van Leeuwen PJ; Baars PC; Nieuwenhuijzen JA; van Haarst EP; Oddens JR; Donswijk ML; van Riel LAMJG; Scheltema MJ; Meijer D; Hendrikse NH; Oprea-Lager DE; Vis AN
BJU Int; 2023 Dec; 132(6):705-712. PubMed ID: 37620288
[TBL] [Abstract][Full Text] [Related]
17.
Zhang LL; Li WC; Xu Z; Jiang N; Zang SM; Xu LW; Huang WB; Wang F; Sun HB
Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):483-492. PubMed ID: 32734457
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic Performance and Clinical Impact of PSMA PET/CT versus mpMRI in Patients with a High Suspicion of Prostate Cancer and Previously Negative Biopsy: A Prospective Trial (PROSPET-BX).
Lopci E; Lazzeri M; Colombo P; Casale P; Buffi NM; Saita A; Peschechera R; Hurle R; Marzo K; Leonardi L; Morenghi E; Balzarini L; Disconzi L; Guazzoni G; Chiti A; Lughezzani G
Urol Int; 2023; 107(5):433-439. PubMed ID: 36724746
[TBL] [Abstract][Full Text] [Related]
19. The PRIMARY Score: Using Intraprostatic
Emmett L; Papa N; Buteau J; Ho B; Liu V; Roberts M; Thompson J; Moon D; Sheehan-Dare G; Alghazo O; Agrawal S; Murphy D; Stricker P; Hope TA; Hofman MS
J Nucl Med; 2022 Nov; 63(11):1644-1650. PubMed ID: 35301240
[TBL] [Abstract][Full Text] [Related]
20. Prospective Evaluation of
Lopci E; Lughezzani G; Castello A; Saita A; Colombo P; Hurle R; Peschechera R; Benetti A; Zandegiacomo S; Pasini L; Casale P; Pietro D; Bevilacqua G; Balzarini L; Buffi NM; Guazzoni G; Lazzeri M
Eur Urol Focus; 2021 Jul; 7(4):764-771. PubMed ID: 32312701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
